A study to evaluate the efficacy and safety of Tolvaptan in heart failure patients with peritoneal dialysis

A study to evaluate the efficacy and safety of Tolvaptan in heart failure patients with peritoneal dialysis - A study to evaluate the efficacy and safety of Tolvaptan in heart failure patients with peritoneal dialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009228

Enrollment

Registered

2012-10-31

Start date

2012-10-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease , heart failure

Interventions

tolvaptan 7.5mg/day (can be escalated to 15mg, if needed)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.patients with congestive heart failure 2. patients who already have existing diuretics 3. patients with peritoneal dialysis 4. inpatients

Exclusion criteria

Exclusion criteria: 1.patients who have a history of allergy against tolvaptan or similar compounds 2.anuric patients (urinary output: <100mL/day) 3.patients who cannnot feel thirsty or have difficulty to drink 4.patients whose serum sodium level is over 147mEq/L 5.pregnant or possibly pregnant woman 6. patients who already have taken tolvaptan at randomization 7.patients regarded as inappropriate for this clinical study by the investigator

Design outcomes

Primary

Measure	Time frame
change of urine volume	—

Secondary

Measure	Time frame
1)change of body weight 2)change of serum electrolyte 3)sCre,eGFR 4) peritoneal function 5)ANP/BNP 6) urine electrolyte 7) serum osmolarity, urine osmolarity 8)Kt/V	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026